We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Copper Therapy Cures ALS Mouse Model

By LabMedica International staff writers
Posted on 09 Feb 2016
Print article
Image: Copper, zinc superoxide dismutase (Cu Zn SOD) is essential to life, but when damaged can become toxic (Photo courtesy of Oregon State University).
Image: Copper, zinc superoxide dismutase (Cu Zn SOD) is essential to life, but when damaged can become toxic (Photo courtesy of Oregon State University).
Selective delivery of copper (Cu) to the central nervous system effectively treats the motor neuron disease amyotrophic lateral sclerosis (ALS) in the most widely used mouse model of the disorder.

ALS is a progressive and fatal neurodegenerative disease caused by the death and deterioration of motor neurons in the spinal cord that is linked to mutations in the enzyme copper, zinc superoxide dismutase (Cu, Zn SOD). Copper helps to stabilize the three-dimensional structure of this antioxidant enzyme, but when it lacks metal co-factors, SOD can unfold and become toxic, leading to the death of motor neurons.

Over-expression of mutant Cu, Zn SOD in mice induces ALS and has become the most widely used model of neurodegeneration. However, no pharmaceutical agent in 20 years has extended lifespan of these animals by more than a few weeks.

The Copper-Chaperone-for-SOD (CCS) protein completes the maturation of SOD by inserting copper, but paradoxically mice that have been genetically engineered to express human CCS while co-expressing mutant SOD die within two weeks of birth.

Hypothesizing that co-expression of CCS created copper deficiency in the spinal cord, investigators at Oregon State University (Corvallis, USA) treated these baby mice with the PET (positron emission tomography)-imaging agent CuATSM (diacetyl-bis(N4-methylthiosemicarbazone)), which is known to deliver copper into the central nervous system within minutes.

The investigators reported in the January 27, 2016, online edition of the journal Neurobiology of Disease that CuATSM prevented the early mortality of the CCSxSOD mice, while markedly increasing the level of Cu, Zn SOD protein in their ventral spinal cords. Remarkably, continued treatment with CuATSM extended the survival of these mice by an average of 18 months. When CuATSM treatment was stopped, these mice developed ALS-related symptoms and died within three months. Restoring CuATSM treatment could rescue these mice after they became symptomatic, providing a means to start and stop disease progression.

All human ALS patients express CCS, raising the hope that familial ALS patients could respond to CuATSM treatment similarly to the CCSxSOD mice.

"We are shocked at how well this treatment can stop the progression of ALS," said senior author Dr. Joseph Beckman, professor of biochemistry and at Oregon State University. "We have a solid understanding of why the treatment works in the mice, and we predict it should work in both familial and possibly sporadic human patients, but we will not know until we try. We want people to understand that we are moving to human trials as quickly as we can. In humans who develop ALS, the average time from onset to death is only three to four years."

Related Links:

Oregon State University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.